Drastic changes to Ampligen clinical trial hurts ME patients – sign the petition to fight it

Author:

Share on facebook
Share on twitter
Share on email

Patients in the Ampligen clinical trial are bearing the brunt of drastic changes Hemispherx has implemented that will force many to stop getting this medicine and may endanger prospects for FDA approval.
We need the community’s help in telling Hemispherx to put patients first, so we can continue to fight for FDA approval of the first medicine for ME. Sign the petition.
Four changes made by the drug maker are forcing patients off the medicine and threaten the continuation of the clinical trial:

  1. A 167% price increase.
  2. Ending the compassionate care program, which supports less than a handful of patients who need the assistance.
  3. Restricting access to current full-time enrollees only, which is prohibiting participants who take a “break” or holiday from the drug.
  4. Closing the trial to new participants.

These changes obviously affect those who are in the trial, but they also restrict future access to ME patients.
Ampligen patients have met with the company and petitioned the Board of Hemispherx saying: “Hemispherx’s changes to the program are predatory and cruel, given the desperate need for treatment among this patient population.”
Meanwhile, Hemispherx announced this week that it was shipping Ampligen inventory to Europe for use in the Early Access Program in the EU.
Ampligen patients also believe these drastic changes will harm prospects for FDA approval of this first ME medication, pointing out  to the company the central role patients have played in pushing the FDA to recognize ME and approve Ampligen:
“Patients on Ampligen have been the force behind urging the FDA to approve it. We have led dramatic efforts to change FDA’s beliefs about the disease and Ampligen’s efficacy, including 700 testimonies during the advisory committee hearing, a 5,000 plus petition to the FDA, a patient hunger strike protesting FDA denial, a stakeholder and other important meetings at FDA, and Congressional and HHS outreach.”
The entire ME community has an interest in the successful pursuit of FDA approval for the first medicine for our disease. Approval of the first ME medication will lead to more clinical trials and investment by the larger pharmaceutical industry. Reducing the Ampligen trial is not a successful strategy for FDA approval.
Please join Ampligen patients in making sure Hemispherx puts ME patients first to prevent damage to participants’ health and future approval prospects.
Sign the petition to tell Hemispherx to reverse these draconian changes to the Ampligen clinical trial that will hurt the ME community.
 

Share on facebook
Facebook
Share on twitter
Twitter
Share on whatsapp
WhatsApp
Share on google
Google+
Share on email
Email

2 thoughts on “Drastic changes to Ampligen clinical trial hurts ME patients – sign the petition to fight it”

  1. This type of issue requires civil disobedience targeting the pharma company. I would be surprised if pharma did anything after receiving a petition.

  2. I seriously do not understand this article.
    To the best of my knowledge, there is no current trial of Ampligen in the US. So how can there be any changes to it, if it doesn’t exist?

Leave a Comment

Your email address will not be published. Required fields are marked *

Latest News

Sign petition To Fix ME/CFS tracking In US!

In August, we shared with you that we and six other ME/CFS organizations had submitted a proposal to the National Center of Health Statistics (NCHS) to fix the coding of ME/CFS in the US International Classification of Diseases (ICD-10-CM). Today, we are writing with an update on that proposal and asking that you sign the

Read More »

NICE announces roundtable event to ensure implementation of ME/CFS guideline

NICE announced today that it will hold a roundtable in September as the next step in the publication of the ME/CFS guideline. The roundtable will include representatives from patient organisations and charities, relevant professional societies, NHS England and NHS Improvement, NICE and the guideline committee. It aims to, “better understand the issues raised and determine

Read More »

#MEAction & 6 ME Orgs Call for CDC to Change How it Tracks ME/CFS

Together with six other organizations, we have submitted a proposal to the National Center for Health Statistics (NCHS) to add myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) to the neurological chapter of the International Classification of Diseases (ICD-10-CM).  Today, ME/CFS does not exist in the US ICD-10-CM. Instead,  most US doctors assign the code for chronic fatigue

Read More »

Help keep our work going

We rely on donations from people like you to keep fighting for equality for people with ME.

Donate

Get actions alerts and news direct to your inbox

You can choose what you want to be kept up to date on.

Subscribe
Scroll to Top